Kane Biotech to Showcase Technologies and Products at the 2019 BIO International Convention
May 29 2019 - 3:15PM
Kane Biotech Inc. (TSX-V:KNE), (the “Corporation” or “Kane
Biotech”), a biotechnology company engaged in the research,
development and commercialization of technologies and products that
prevent and remove microbial biofilms, is pleased to announce that
it will be attending the 2019 BIO International Convention being
held June 3-6, 2019 at the Philadelphia Convention Center in
Philadelphia, PA. Marc Edwards, Chief Executive Officer, and Dr.
Gordon Guay, Chief Scientific Officer, will be attending the
convention and hosting Kane Biotech’s exhibit booth (#2417). The
team will be showcasing Kane’s technologies and products that break
up bacterial biofilms in the human and animal health markets.
Management will also participate in meetings with potential
clinical and commercial partners, investors, and other parties
throughout the conference.
Kane Biotech’s booth is located on the floor of the Expo and
will showcase numerous products and technologies of the Corporation
including DispersinB® and Bluestem oral care products.
Investors, potential partners, and interested parties attending
the conference who would like to meet with Kane Biotech management
and scientists are encouraged to contact Kane Biotech Investor
Relations at lyonker@edisongroup.com.
About BIO
BIO is the world's largest trade association representing
biotechnology companies, academic institutions, state biotechnology
centers and related organizations across the United States and in
more than 30 other nations. BIO members are involved in the
research and development of innovative healthcare, agricultural,
industrial and environmental biotechnology products. BIO also
produces the BIO International Convention, the world’s largest
gathering of the biotechnology industry, along with
industry-leading investor and partnering meetings held around the
world. BIOtechNOW is BIO's blog chronicling “innovations
transforming our world” and the BIO Newsletter is the
organization’s bi-weekly email newsletter.
The BIO International Convention (BIO) attracts 16,000+
biotechnology and pharma leaders who come together for one week of
intensive networking to discover new opportunities and promising
partnerships. The Convention brings together a wide spectrum of
life science and application areas including drug discovery,
biomanufacturing, genomics, biofuels, nanotechnology and cell
therapy.
About Kane Biotech
Kane Biotech is a biotechnology company engaged in the research,
development and commercialization of technologies and products that
prevent and remove microbial biofilms. The Corporation has a
portfolio of biotechnologies, intellectual property (58 patents and
patents pending, trade secrets and trademarks) and products
developed by the Corporation’s own biofilm research expertise and
acquired from leading research institutions. StrixNB(TM),
DispersinB(R), Aledex(R), bluestem(TM), AloSera(TM), coactiv+(TM)
and Kane(R) are trademarks of Kane Biotech Inc. The Corporation is
listed on the TSX Venture Exchange under the symbol "KNE".
For more information, please visit
www.kanebiotech.com, or contact:
Marc EdwardsChief Executive OfficerKane Biotech
Inc.
+1 (514)
910-6991 medwards@kanebiotech.com
Ray DupuisChief Financial OfficerKane Biotech Inc.+1 (204)
298-2200 rdupuis@kanebiotech.com
Joe Green US. Investor Relations Edison Inc. +1 (646)
653-7030
jgreen@edisongroup.com
Laine YonkerUS. Investor RelationsEdison Inc. +1 (646) 653
7035
lyonker@edisongroup.com
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this release.
Caution Regarding Forward-Looking
Information
This press release contains certain statements regarding Kane
Biotech Inc. that constitute forward-looking information under
applicable securities law. These statements reflect management’s
current beliefs and are based on information currently available to
management. Certain material factors or assumptions are applied in
making forward-looking statements, and actual results may differ
materially from those expressed or implied in such statements.
These risks and uncertainties include, but are not limited to,
risks relating to the Company’s: (a) financial condition, including
lack of significant revenues to date and reliance on equity and
other financing; (b) business, including its early stage of
development, government regulation, market acceptance for its
products, rapid technological change and dependence on key
personnel; (c) intellectual property including the ability of the
Company to protect its intellectual property and dependence on its
strategic partners; and (d) capital structure, including its lack
of dividends on its common shares, volatility of the market price
of its common shares and public company costs. Further information
about these and other risks and uncertainties can be found in the
disclosure documents filed by the Company with applicable
securities regulatory authorities, available at www.sedar.com. The
Company cautions that the foregoing list of factors that may affect
future results is not exhaustive.
Kane Biotech (TSXV:KNE)
Historical Stock Chart
From Apr 2024 to May 2024
Kane Biotech (TSXV:KNE)
Historical Stock Chart
From May 2023 to May 2024